It has long been accepted that pituitary-adrenal suppression occurs in the majority of patients treated with corticosteroids in doses of the order of 7 -5 mg. or more daily of prednisolone or equivalent, although it is recognized that there is considerable patient variability. The mechanism of this process is not fully understood, but is attributed to cessation of ACTH release in response to the increased concentration ofcirculating glucocorticoid, and subsequent adrenal atrophy. Moreover, it is not at all clear why patients treated with long-term corticotrophin generally retain hypothalamic-pituitary adrenal responsiveness. We have shown (Carter and James 1970a) that patients receiving therapeutic daily doses of ACTH for periods of 2 years or more were able to produce a normal pituitary-adrenal response to the stress of insulin hypoglycaemia, and were also able to produce a normal increase in plasma cortisol levels while undergoing surgical operations without steroid cover (Carter and James, 1970b).
It has long been accepted that pituitary-adrenal suppression occurs in the majority of patients treated with corticosteroids in doses of the order of 7 -5 mg. or more daily of prednisolone or equivalent, although it is recognized that there is considerable patient variability. The mechanism of this process is not fully understood, but is attributed to cessation of ACTH release in response to the increased concentration ofcirculating glucocorticoid, and subsequent adrenal atrophy. Moreover, it is not at all clear why patients treated with long-term corticotrophin generally retain hypothalamic-pituitary adrenal responsiveness. We have shown (Carter and James 1970a ) that patients receiving therapeutic daily doses of ACTH for periods of 2 years or more were able to produce a normal pituitary-adrenal response to the stress of insulin hypoglycaemia, and were also able to produce a normal increase in plasma cortisol levels while undergoing surgical operations without steroid cover (Carter and James, 1970b) .
On the other hand, surprisingly, no reasonable therapeutic combination of ACTH with corticosteroids could be found which would preserve the integrity of the hypothalamic-pituitary-adrenal (HPA) axis in terms of stress responsiveness; in fact, the suppressive effect of steroids seems to be enhanced rather than offset, as had previously been supposed, by ACTH in the doses used (Carter and James, 1970c) .
A series of studies has been made as part of a research programme with two main objectives:
(1) An attempt to find an improved therapeutic regime employing long-term corticotrophin and/or corticosteroids for patients suffering from chronically active rheumatic diseases-that is, one combining clinical efficacy as well as simplicity and acceptability of administration, with mitigation of side-effects, especially impairment of HPA function;
(2) A parallel aim to acquire from this work a better understanding of the different effects of these substances on the HPA axis.
This paper is concerned with the second objective, and deals with studies of the obvious features of corticotrophin therapy which it was thought might explain the different effects resulting from exogenous ACTH and steroid administration. In particular, we have investigated the dose, frequency, and time of administration, and the pattern of the plasma cortisol levels produced. We have also considered the role of two other steroids, androstenedione and dehydroepiandrosterone sulphate (d-sulphate), which are secreted by the adrenal cortex in response to ACTH, and the possibility of increased adrenocortical sensitivity to ACTH has also been studied.
Material and methods
Of 29 patients studied, eighteen were women and eleven men; 26 were suffering from classical or definite rheumatoid arthritis according to the American Rheumatism Association criteria (Ropes, Bennett, Cobb, Jacox, and Jessar, 1959) Various types of corticotrophin were all given by the intramuscular route: 'Acthar Gel' (Armour), 'ACTH/cmc' (Crookes), 'Cortrophin ZN' (Organon), and 'Cortrosyn' (Organon).
The corticosteroids used were enteric-coated prednisolone, 'Delta Cortril' (Pfizer), hydrocortisone, and specially prepared hydrocortisone tablets which had delayed absorption (Glaxo). Tablets of dehydroepiandrosterone sulphate (Organon) and injections of androstenedione in arachis oil (Organon) were also used.
Plasma cortisol curves to determine the level and duration of activity of different types and doses of ACIH were performed over 48-hr periods, with blood sampling for cortisol levels every two hours. Plasma cortisol was estimated by an automated fluorimetric technique (Townsend and James, 1968) .
Urinary 17-oxogenic steroids were estimated by the method described by James and Caie (1964) . Insulin stress tests were performed as described by Greenwood, Landon, and Stamp (1966) .
Results
The Table shows the mean daily urinary 17-oxogenic steroid excretion of twelve patients collected over a mean period of nine consecutive days per patient. These patients were receiving oral cortisol in doses of 25, 40, 50, 60, or 75 mg./day, and were compared with 26 patients receiving daily intramuscular injections of ACTH (Cortrophin ZN, Cortrosyn or Corticotrophin/cmc.), whose urine was collected over a mean period of seven consecutive days per patient. It can be seen that our commonly employed dose range of ACTH (15-40 units/day) is approximately equivalent in terms of 17-oxogenic excretion to cortisol 37-5 to 100 mg./day, that is to prednisolone 7 * 5 to 20 mg./day (see also (Carter and James, 1970a Fig. 3 (overleaf).
With a view to obtaining blood cortisol curves with oral corticostercd.,s similar to those resulting from an injecticn of ACTH, delayed-absorption tablets of hydrocortisone were specially prepared. Fig. 4 (overleaf) Treatment ('long-acting' cortisol) in divided doses of 10 or 12-5 mg. daily (Fig. 6,  opposite) showed consistently flat responses to insulin hypoglycaemia, as did the five male patients who were given daily intramuscular injections of androstenedione 25 mg. with their daily prednisolone treatment (Fig. 7, opposite the 4th day, prednisolone (20 mg.) was given and blood cortisol levels were estimated at regular intervals throughout surgery. The procedures carried out were pelvic floor repair, posterior tibialis tendon repair, Fowler's operation, and Hofmann's operation. No patient produced any alteration in blood cortisol level, implying that in these conditions ACTH release had not occurred.
ADRENOCORTICAL SENSITIVITY TO ACTH
Sixteen patients who had received continuous daily ACTH treatment in doses ranging from 20 to 40 units per day were studied in the way described by Landon, James, Wharton, and Friedman (1967) cation of increased sensitivity to ACTH was ob-HPA function in ACTH treated patients.
tained. We have studied groups of patients receiving equivalent therapeutic doses of ACTH and of predDiscussion nisolone and have concluded that the difference in HPA function in the two groups is not simply a None of the several factors investigated in this study question of the amount of steroid to which they are appears to be of significance in the preservation of exposed. Neither does it seem likelv that the dif- Bacon, Daly, Myles, and Savage (1968) have suggested that, when shorter acting ACTH preparations are given once daily, there is a period during the 24 hours in which the plasma cortisol levels are low, thus perhaps protecting the HPAaxis from suppression. However, twice daily administration of ACTH (Fig. 1) does not significantly impair HPA function. In addition, the time at which ACTH is given does not appear to be relevant, since even evening administration of ACTH does not cause HPA suppression (Fig. 2) , even though this mode of therapy will tend to produce high plasma cortisol levels at a time when endogenous ACTH release occurs. In contrast, this is the time at which oral steroid will cause HPA suppression most effectively (Nichols, Nugent, and Tyler, 1965) .
In seeking further differences between ACTH and corticosteroid therapy, we considered the possibility that the pattern of the plasma steroid might be of importance. As shown in Fig. 3 , there is a marked difference between the pattern of blood cortisol after an intramuscular injection of ACTH and that after the ingestion of cortisol tablets, both the level reached and the duration of elevation being different. However, even when the plasma cortisol changes induced by ACTH were mimicked exactly by using delayed-absorption cortisol tablets, suppression occurred rapidly. The hypothesis that the pattern of plasma cortisol level is important in influencing the integrity of the HPA system therefore appears to be untenable.
Si In summary, then, we have been unable to find an explanation for the failure of ACTH to cause suppression of HPA function. Of the several factors studied, the dose, time of administration, role of other adrenal steroids, and adrenocortical sensitivity did not appear to be of major importance. Nevertheless, as we have shown elsewhere (Carter and James, 1970a) , ACTH therapy does produce some abnormality of endogenous ACTH release, as revealed by the failure of some patients to respond when challenged with lysine vasopressin.
It seems likely that direct measurement of plasma ACTH levels may shed further light on these problems, the solution of which would have both theoretical and practical importance. Summary 29 patients with chronic inflammatory polyarthritis receiving corticotrophin (ACTH) or corticosteroid therapy administered in varying schedules were studied, in order to seek an explanation for the different effects of these two drugs on the hypothalamic-pituitary adrenal system. The obvious possible reasons for the retention of pituitaryadrenal responsiveness in patients receiving longterm corticotrophin were investigated; results of these studies show that the dose of ACTH employed, the frequency of injections, the time of administration in relation to the diurnal rhythm of blood cortisol, and the cortisol pattern following an ACTH injection are apparently irrelevant. The other major adrenal hormones, dehydroepiandrosterone Effects of corticotrophin and corticosteroids on pituitary-adrenalfunction 97 and androstenedione, which are released from the and we are also grateful to Armour, Crookes, Glaxo, and adrenal by ACTH, do not afford protection from Organon Laboratories for additional assistance. suppression, at least in the doses used in this study.
In particular we wish to thank Glaxo Laboratories for providing delayed-action cortisol tablets and the Organon
